Skip to main content
SpringerLink
Log in
Book cover

Androgenetic Alopecia From A to Z pp 77–95Cite as

Dutasteride

  • 437 Accesses

Abstract

Dutasteride is a synthetic 4-azasteroid, developed by GlaxoSmithKline, and it is an orally-administered, second generation inhibitor of the 5α-R enzymatic complex that leads to near-maximal Dihydrotestosterone (DHT) suppression. The compound appeared in the medical literature initially under the name GG-745, later as GI198745, and was finally named Dutasteride [1]. Dutasteride is commercially available under the brand name Avodart® (Dutasteride 0.5 mg), containing soft capsules of a mixture of mono- and diglycerides of capric/caprylic acid. Dutasteride is soluble in organic solvents, such as ethanol (44 mg/mL), methanol (64 mg/mL), and polyethylene glycol 400 (3 mg/mL), but it is insoluble in water (<0.038 ng/mL) [2].

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G. Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol. 1998;11:393–422.

    CAS  PubMed  Google Scholar 

  2. US Food Drug Administration Center for Drug Evaluation and Research. Application Number 21–319 Clinical pharmacology and biopharmaceutics review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_biopharmr_P1.pdf. Accessed 4 Mar 2013.

  3. Tian G, Mook RA Jr, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry. 1995;34(41):13453–9.

    CAS  PubMed  Google Scholar 

  4. Frye SV. Discovery and clinical development of Dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem. 2006;6(5):405–21.

    CAS  PubMed  Google Scholar 

  5. Foley CL, Kirby RS. 5 Alpha-reductase inhibitors: what’s new? Curr Opin Urol. 2003;13(1):31–7.

    PubMed  Google Scholar 

  6. Stuart JD, Lee FW, et al. Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 5steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and Finasteride in the rat. Biochem Pharmacol. 2001;62(7):933–42.

    CAS  PubMed  Google Scholar 

  7. Andriole G, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Pt 1):1399–403.

    CAS  PubMed  Google Scholar 

  8. Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology. 1996;193(3):177–84.

    CAS  PubMed  Google Scholar 

  9. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995;105(2):209–14.

    CAS  PubMed  Google Scholar 

  10. Olsson Gisleskog P, Hermann D, Hammarlund-Udenaes M, Karlsson MO. Validation of a population pharmacokinetic/pharmacodynamic model for 5alpha-reductase inhibitors. Eur J Pharm Sci. 1999;8(4):291–9.

    CAS  PubMed  Google Scholar 

  11. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002;19(6):413–25.

    CAS  PubMed  Google Scholar 

  12. Andriole G, Ray P, Humphrey P, Gleave M, Rittmaster R. The impact of Dutasteride , a novel dual 5α-reductase inhibitor on both serum and intraprostatic androgens. Abstract presented at the 18th Congress of the European Association of Urology; Madrid, Spain; 12–15 March 2003.

    Google Scholar 

  13. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther. 1998;64(6):636–47.

    CAS  PubMed  Google Scholar 

  14. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor Dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44(1):82–8.

    CAS  PubMed  Google Scholar 

  15. Jacobsen SJ, Cheetham TC, Haque R, Shi JM, Loo RK. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA. 2008;300(14):1660–4.

    CAS  PubMed  Google Scholar 

  16. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89(5):2179–84.

    CAS  PubMed  Google Scholar 

  17. GlaxoSmithKline. Prescribing information: Avodart (Dutasteride) soft gelatin capsules. Triangle Park: GlaxoSmith-Kline; 2004.

    Google Scholar 

  18. Keam SJ, Scott LJ. Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463–85.

    CAS  PubMed  Google Scholar 

  19. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. The pharmacokinetic modelling of GI198745 (Dutasteride), a compound with parallel linear and nonlinear elimination. Br J Clin Pharmacol. 1999;47(1):53–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496–502.

    CAS  PubMed  Google Scholar 

  21. Cai G, Thiessen JJ, Baidoo CA, Fossler MJ. Operating characteristics of a partial-block randomized crossover bioequivalence study for dutasteride, a drug with a long half-life: investigation through simulation and comparison with final results. J Clin Pharmacol. 2010;50(10):1142–50.

    CAS  PubMed  Google Scholar 

  22. GlaxoSmithKline UK. Avodart: summary of prescribing information. https://www.medicines.org.uk/emc

  23. Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications employed in treating benign prostatic hyperplasia and food - a short review. Biomed Pharmacother. 2016;83:1141–5.

    PubMed  Google Scholar 

  24. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60(3):434–41.

    PubMed  Google Scholar 

  25. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004;63(4):709–15.

    PubMed  Google Scholar 

  26. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor Dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46(4):488–94.

    CAS  PubMed  Google Scholar 

  27. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS, Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of Dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–23.

    PubMed  Google Scholar 

  28. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8.

    CAS  PubMed  Google Scholar 

  29. Choi GS, Kim JH, Oh SY, Park JM, Hong JS, Lee YS, Lee WS. Safety and tolerability of the dual 5-alpha reductase inhibitor dutasteride in the treatment of androgenetic alopecia. Ann Dermatol. 2016;28(4):444–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Christian JC, Kang KW. Efficiency of human monozygotic twins in studies of blood lipids. Metabolism. 1972;21(8):691–9.

    CAS  PubMed  Google Scholar 

  31. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6(1):9–13.

    PubMed  Google Scholar 

  32. Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–98.

    CAS  PubMed  Google Scholar 

  33. Tsunemi Y, Irisawa R, Yoshiie H, Brotherton B, Ito H, Tsuboi R, Kawashima M, Manyak M, ARI114264 Study Group. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol. 2016;43(9):1051–8.

    CAS  PubMed  Google Scholar 

  34. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708–12.

    PubMed  Google Scholar 

  35. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Park KC, Huh CH. Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351–7.

    CAS  PubMed  Google Scholar 

  36. Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47–54.

    PubMed  Google Scholar 

  37. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res. 1997;57(6):1020–2.

    CAS  PubMed  Google Scholar 

  38. Rajender S, Vijayalakshmi K, Pooja S, Madhavi S, Paul SF, Vettriselvi V, Shroff S, Singh L, Thangaraj K. Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men. J Androl. 2009;30(6):703–10.

    CAS  PubMed  Google Scholar 

  39. Chung HC, Lee S, Lee WS. Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients. J Dermatol. 2017;44(12):1408–9.

    CAS  PubMed  Google Scholar 

  40. Vañó-Galván S, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020;33(1):e13182.

    PubMed  Google Scholar 

  41. Blumeyer A, Tosti A, et al. European Dermatology Forum (EDF). Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6):S1–57.

    PubMed  Google Scholar 

  42. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22.

    CAS  PubMed  Google Scholar 

  43. Camacho F, Tosti A. Tratamiento médico de las alopecias femeninas. Monogr Dermatol. 2005;18:92–117.

    Google Scholar 

  44. Camacho F. La pérdida del cabello en la mujer. In: Grimalt R, editor. Cuidemos de nuestro pelo. Barcelona: Farmalia Com. Ed; 2007. p. 61–103.

    Google Scholar 

  45. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4(5):637–40.

    PubMed  Google Scholar 

  46. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014;80(6):521–5.

    PubMed  Google Scholar 

  47. Georgala S, Katoulis AC, Befon A, Danopoulou I, Georgala C. Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride. J Am Acad Dermatol. 2009;61(1):157–8.

    PubMed  Google Scholar 

  48. Tan KT, Messenger AG. Frontal fibrosing alopecia: clinical presentations and prognosis. Br J Dermatol. 2009;160(1):75–9.

    CAS  PubMed  Google Scholar 

  49. Katoulis A, Georgala BE, Papadavid E, Kalogeromitros D, Stavrianeas N. Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus. J Eur Acad Dermatol Venereol. 2009;23(5):580–2.

    CAS  PubMed  Google Scholar 

  50. Epstein ES. Finasteride and prostate cancer. Hair Transplant Forum Int. 2011;21(5):144–7.

    Google Scholar 

  51. GlaxoSmithKline protocol ΑRI40001.

    Google Scholar 

  52. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388–94.

    CAS  PubMed  Google Scholar 

  53. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64(3):537–41.

    CAS  PubMed  Google Scholar 

  54. Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005;7(4):203–10.

    PubMed  PubMed Central  Google Scholar 

  55. Andriole G, Bostwick D, REDUCE Study Group, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172(4 Pt 1):1314–7.

    CAS  PubMed  Google Scholar 

  56. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.

    CAS  PubMed  Google Scholar 

  57. Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (Review). Oncol Lett. 2014;8(4):1391–6.

    PubMed  PubMed Central  Google Scholar 

  58. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.

    CAS  PubMed  Google Scholar 

  59. Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367–79.

    PubMed  PubMed Central  Google Scholar 

  60. Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract. 2012;66(11):1052–5.

    CAS  PubMed  Google Scholar 

  61. Gupta AK, Carviel J, MacLeod MA, Shear N. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069–75.

    CAS  PubMed  Google Scholar 

  62. Said MA, Mehta A. The impact of 5α-reductase inhibitor use for male pattern hair loss on men’s health. Curr Urol Rep. 2018;19(8):65.

    PubMed  Google Scholar 

  63. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8(3):872–84.

    CAS  PubMed  Google Scholar 

  64. Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554–66.

    CAS  PubMed  Google Scholar 

  65. Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011;8(11):3066–74.

    CAS  PubMed  Google Scholar 

  66. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase (iNOS) on the physiology and pathology of penile erection. Curr Pharm Des. 2005;11(31):4041–6.

    CAS  PubMed  Google Scholar 

  67. Chi BH, Kim SC. Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results. Korean J Urol. 2011;52(9):632–6.

    PubMed  PubMed Central  Google Scholar 

  68. Traish A, Haider KS, Doros G, Haider A. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017;30(3)

    Google Scholar 

  69. Na Y, Ye Z, Zhang S, Chinese Dutasteride Phase III Trial (ARIA108898) Study Group. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension. Clin Drug Investig. 2012;32(1):29–39.

    CAS  PubMed  Google Scholar 

  70. Liu L, Zhao S, Li F, Li E, Kang R, Luo L, Luo J, Wan S, Zhao Z. Effect of 5α-reductase inhibitors on sexual function: a meta-analysis and systematic review of randomized controlled trials. J Sex Med. 2016;13(9):1297–310.

    PubMed  Google Scholar 

  71. Corona G, Tirabassi G, Santi D, Maseroli E, Gacci M, Dicuio M, Sforza A, Mannucci E, Maggi M. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology. 2017;5(4):671–8.

    CAS  PubMed  Google Scholar 

  72. Tsai TF, Choi GS, Kim BJ, Kim MB, Ng CF, Kochhar P, Jasper S, Brotherton B, Orban B, Lulic Z. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol. 2018;45(7):799–804.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Lee S, Lee YB, Choe SJ, Lee WS. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis. Acta Derm Venereol. 2019;99(1):12–7.

    CAS  PubMed  Google Scholar 

  74. Traish AM. Negative impact of testosterone deficiency and 5α-reductase inhibitors therapy on metabolic and sexual function in men. Adv Exp Med Biol. 2017;1043:473–526.

    CAS  PubMed  Google Scholar 

  75. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–65.

    CAS  PubMed  Google Scholar 

  76. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56–62.

    PubMed  PubMed Central  Google Scholar 

  77. Russell DW, Berman DM, Bryant JT, Cala KM, Davis DL, Landrum CP, Prihoda JS, Silver RI, Thigpen AE, Wigley WC. The molecular genetics of steroid 5 alpha-reductases. Recent Prog Horm Res. 1994;49:275–84.

    CAS  PubMed  Google Scholar 

  78. Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh QD. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021;157(1):35–42.

    PubMed  Google Scholar 

  79. Thiboutot D, Bayne E, Thorne J, Gilliland K, Flanagan J, Shao Q, Light J, Helm K. Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin. Arch Dermatol. 2000;136(9):1125–9.

    CAS  PubMed  Google Scholar 

  80. Sharma P, Jain D, Maithani M, Mishra SK, Khare P, Jain V, Singh R. Development and characterization of dutasteride bearing liposomal systems for topical use. Curr Drug Discov Technol. 2011;8(2):136–45.

    CAS  PubMed  Google Scholar 

  81. Xie X, Yang Y, Chi Q, Li Z, Zhang H, Li Y, Yang Y. Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies. PLoS One. 2014;9(12):e114835.

    PubMed  PubMed Central  Google Scholar 

  82. Madheswaran T, Baskaran R, Sundaramoorthy P, Yoo BK. Enhanced skin permeation of 5α-reductase inhibitors entrapped into surface-modified liquid crystalline nanoparticles. Arch Pharm Res. 2015;38(4):534–42.

    CAS  PubMed  Google Scholar 

  83. Madheswaran T, Baskaran R, Yoo BK, Kesharwani P. In vitro and in vivo skin distribution of 5α-reductase inhibitors loaded into liquid crystalline nanoparticles. J Pharm Sci. 2017. pii: S0022–3549(17)30485–9

    Google Scholar 

  84. Noor NM, Sheikh K, Somavarapu S, Taylor KMG. Preparation and characterization of dutasteride-loaded nanostructured lipid carriers coated with stearic acid-chitosan oligomer for topical delivery. Eur J Pharm Biopharm. 2017;117:372–84.

    CAS  PubMed  Google Scholar 

  85. Ushirobira CY, Afiune LAF, Pereira MN, Cunha-Filho M, Gelfuso GM, Gratieri T. Dutasteride nanocapsules for hair follicle targeting: Effect of chitosan-coating and physical stimulus. Int J Biol Macromol. 2020;151:56–61.

    CAS  PubMed  Google Scholar 

  86. Noor NM, Abdul-Aziz A, Sheikh K, Somavarapu S, Taylor KMG. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020;12(10):994.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Park SJ, Choo GH, Hwang SJ, Kim MS. Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride. Arch Pharm Res. 2013;36(5):593–601.

    CAS  PubMed  Google Scholar 

  88. Kim MS, Ha ES, Choo GH, Baek IH. Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system. Int J Mol Sci. 2015;16(5):10821–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Beak IH, Kim MS. Improved supersaturation and oral absorption of Dutasteride by amorphous solid dispersions. Chem Pharm Bull (Tokyo). 2012;60(11):1468–73.

    CAS  PubMed  Google Scholar 

  90. Kim MS. Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs. Artif Cells Nanomed Biotechnol. 2013;41(6):363–7.

    CAS  PubMed  Google Scholar 

  91. Choo GH, Park SJ, Hwang SJ, Kim MS. Formulation and in vivo evaluation of a self-microemulsifying drug delivery system of dutasteride. Drug Res (Stuttg). 2013;63(4):203–9.

    PubMed  Google Scholar 

  92. Kim MS. Evaluation of in vitro dissolution and in vivo oral absorption of dutasteride-loaded eudragit E nanoparticles. Drug Res (Stuttg). 2013;63(6):326–30.

    PubMed  Google Scholar 

  93. El-Komy M, Hassan A, Tawdy A, Solimon M, Hady MA. Hair loss at injection sites of mesotherapy for alopecia. J Cosmet Dermatol. 2017;16(4):e28–30.

    PubMed  Google Scholar 

  94. Afiune LAF, Ushirobira CY, Barbosa DPP, de Souza PEN, Leles MIG, Cunha-Filho M, Gelfuso GM, Soler MAG, Gratieri T. Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia. Int J Pharm. 2020;587:119709.

    CAS  PubMed  Google Scholar 

  95. Mysore V. Mesotherapy in management of hairloss - is it of any use? Int J Trichol. 2010;2(1):45–6.

    Google Scholar 

  96. Kadry R, Hamadah I, Al-Issa A, Field L, Alrabiah F. Multifocal scalp abscess with subcutaneous fat necrosis and scarring alopecia as a complication of scalp mesotherapy. J Drugs Dermatol. 2008;7(1):72–3.

    PubMed  Google Scholar 

  97. Abdallah MA, El-Zawahry KA, Besar HA. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan-Arab League Dermatol. 2009;20:137–45.

    Google Scholar 

  98. Moftah N, Moftah N, Abd-Elaziz G, Ahmed N, Hamed Y, Ghannam B, Ibrahim M. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatol Venereol. 2013;27(6):686–93.

    CAS  PubMed  Google Scholar 

  99. Sobhy N, Aly H, Shafee AE, Deeb ME. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol Online. 2013;4(1):40–5.

    Google Scholar 

  100. Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, Jaén-Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143–5.

    PubMed  PubMed Central  Google Scholar 

  101. Moftah N, Mubarak R, Abdelghani R. Clinical, trichoscopic, and folliscopic identification of the impact of metabolic syndrome on the response to intradermal dutasteride 0.02% injection in patients with female pattern hair loss; a prospective cohort study. J Dermatolog Treat. 201;32(7):827–36.

    Google Scholar 

  102. Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, de León-Gutiérrez H, Ocampo-Garza SS, Gómez-Flores M, Grimalt R. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338–45.

    PubMed  PubMed Central  Google Scholar 

  103. Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia. Jun: Australas J Dermatol; 2012.

    Google Scholar 

  104. Bayne EK, Flanagan J, et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol. 1999;141(3):481–91.

    CAS  PubMed  Google Scholar 

  105. Pindado-Ortega C, Saceda-Corralo D, Fernández-Nieto D, Jiménez-Cauhé J, Ortega-Quijano D, Moreno-Arrones ÓM, Vañó-Galván S. Prescribing habits for androgenic alopecia among dermatologists in Spain in 2019-2020: a cross-sectional study. Skin Appendage Disord. 2020;6(5):283–6.

    PubMed  PubMed Central  Google Scholar 

  106. Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399–406.

    CAS  PubMed  PubMed Central  Google Scholar 

  107. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186(4170):1213–5.

    CAS  PubMed  Google Scholar 

  108. Imperato-McGinley J, Peterson RE, Gautier T, Sturla E. Male pseudohermaphroditism secondary to 5 alpha-reductase deficiency—a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem. 1979;11(1B):637–45.

    CAS  PubMed  Google Scholar 

  109. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974;291(18):944–9.

    CAS  PubMed  Google Scholar 

  110. Rhie A, Son HY, Kwak SJ, Lee S, Kim DY, Lew BL, Sim WY, Seo JS, Kwon O, Kim JI, Jo SJ. Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. PLoS One. 2019;14(9):e0222533.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Rittmaster RS. Finasteride. N Engl J Med. 1994;330(2):120–5.

    CAS  PubMed  Google Scholar 

  112. Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy. 1993;13(4):309–25.

    CAS  PubMed  Google Scholar 

  113. Burinsky DJ, Williams JD, Thornquest AD Jr, Sides SL. Mass spectral fragmentation reactions of a therapeutic 4-azasteroid and related compounds. J Am Soc Mass Spectrom. 2001;12(4):385–98.

    CAS  PubMed  Google Scholar 

  114. Evans HC, Goa KL. Dutasteride. Drugs Aging. 2003;20(12):905–16.

    CAS  PubMed  Google Scholar 

  115. Dutasteride tablets approved draft labeling. Application number 21–319.

    Google Scholar 

  116. Shin SY, Shin YH, Lee SW, Shin JY, Kim CH. Blood donors on teratogenic drugs and donor deferral periods in a clinical situation. Vox Sang. 2012;102(4):362–4.

    CAS  PubMed  Google Scholar 

  117. Mahendroo MS, Russell DW. Male and female isoenzymes of steroid 5alpha-reductase. Rev Reprod. 1999;4(3):179–83.

    CAS  PubMed  Google Scholar 

  118. Manabe M, Tsuboi R, Itami S, Drafting Committee for the Guidelines for the Diagnosis and Treatment of Male- and Female-Pattern Hair Loss, et al. Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version. J Dermatol. 2018;45(9):1031–43. https://doi.org/10.1111/1346-8138.14470.

    CrossRef  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Athens, Attiki, Greece

    Konstantinos Anastassakis

Authors
  1. Konstantinos Anastassakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anastassakis, K. (2022). Dutasteride. In: Androgenetic Alopecia From A to Z . Springer, Cham. https://doi.org/10.1007/978-3-031-08057-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-08057-9_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-08056-2

  • Online ISBN: 978-3-031-08057-9

  • eBook Packages: MedicineMedicine (R0)

search

Navigation